Journal
ACS OMEGA
Volume 5, Issue 46, Pages 29733-29745Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acsomega.0c03505
Keywords
-
Categories
Funding
- Thailand Research Fund [RSA5880007]
- Royal Golden Jubilee Ph.D. (RGJ-Ph.D.) Program [PHD/0198/2556, PHD/0052/2557]
- Faculty of Medicine Research Fund, Chiang Mai University [045/2561, 095/2561]
- Robert A. Welch Foundation [E-1320]
Ask authors/readers for more resources
Perylene diimide (PDI) derivatives have been studied as G-quadruplex ligands that suppress telomerase activity by facilitating G-quadruplex formation of telomeric DNA and the hTERT promoter. PIPER, the prototypical PDI, reduces telomerase activity in lung and prostate cancer cells, leading to telomere shortening and cellular senescence of these cells. However, PIPER suffers from poor hydrosolubility and the propensity to aggregate at neutral pH. In this report, we synthesized a new asymmetric PDI, aPDI-PHis, which maintains one N-ethyl piperidine side chain of PIPER and has histidine as another side chain. The results show that aPDI-PHis is superior to its symmetric counterparts, PIPER and PDI-His, in terms of hydrosolubility, G-quadruplex binding, cellular uptake, and telomerase inhibition in prostate cancer cells. These results suggest that one N-ethyl piperidine side chain of PDI is sufficient for G-quadruplex binding, while another side chain can be tuned to elicit desirable properties. These findings might lead to better PDIs for use as anticancer drugs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available